ArticlePharmacoEconomics2026

Model-Based Economic Evaluation of the First-in-Class Myosin Inhibitor Mavacamten Versus Care as Usual in Obstructive Hypertrophic Cardiomyopathy Patients from a Dutch Societal Perspective.

Isabell Wiethoff et al.PubMed ↗Publisher ↗

No numbers read from the abstract.